-
Kenya's economy faces climate change risks: World Bank
-
US Fed expected to hold rates steady as Iran war roils outlook
-
It's 'Sinners' v 'One Battle' as Oscars day arrives
-
US mayors push back against data center boom as AI backlash grows
-
Who covers AI business blunders? Some insurers cautiously step up
-
Election campaign deepens Congo's generational divide
-
Courchevel super-G cancelled due to snow and fog
-
Middle East turmoil revives Norway push for Arctic drilling
-
Iran, US threaten attacks on oil facilities
-
Oscars: the 10 nominees for best picture
-
Spielberg defends ballet, opera after Chalamet snub
-
Kharg Island bombed, Trump says US to escort ships through Hormuz soon
-
Jurors mull evidence in social media addiction trial
-
UK govt warns petrol retailers against 'unfair practices' during Iran war
-
Mideast war cuts Hormuz strait transit to 77 ships: maritime data firm
-
How will US oil sanctions waiver help Russia?
-
Oil stays above $100, stocks slide tracking Mideast war
-
How Iranians are communicating through internet blackout
-
Global shipping industry caught in storm of war
-
Why is the dollar profiting from Middle East war?
-
Oil dips under $100, stocks back in green tracking Mideast war
-
US Fed's preferred inflation gauge edges down
-
Deadly blast rocks Iran as leaders attend rally in show of defiance
-
Moscow pushes US to ease more oil sanctions
-
AI agent 'lobster fever' grips China despite risks
-
Thousands of Chinese boats mass at sea, raising questions
-
Casting directors finally get their due at Oscars
-
Fantastic Mr Stowaway: fox sails from Britain to New York port
-
US jury to begin deliberations in social media addiction trial
-
NASA says 'on track' for Artemis 2 launch as soon as April 1
-
Valentino mixes 80s and Baroque splendour on Rome return
-
Dating app Tinder dabbles with AI matchmaking
-
Scavenging ravens memorize vast tracts of wolf hunting grounds: study
-
Top US, China economy officials to meet for talks in Paris
-
Chile's Smiljan Radic Clarke wins Pritzker architecture prize
-
Lufthansa flights axed as pilots walk out
-
Oil tops $100 as fresh Iran attacks offset stockpiles release
-
US military 'not ready' to escort tankers through Hormuz Strait: energy secretary
-
WWII leader Churchill to be removed from UK banknotes
-
EU vows to 'respond firmly' to any trade pact breach by US
-
'Punished' for university: debt-laden UK graduates urge reform
-
Mideast war to brake German recovery: institute
-
China-North Korea train arrives in Pyongyang after 6-year halt
-
Businessman or politician? Billionaire Czech PM under fire again
-
Lost page of legendary Archimedes palimpsest found in France
-
Cathay Pacific roughly doubles fuel surcharge on most routes
-
BMW profit holds up despite Trump tariffs, China woes
-
Electric vehicle rethink to cost Honda almost $16 billion
-
From Kyiv to UK, Ukrainian drone production spans Europe
-
Australia to change fuel quality standards to boost supply
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
J.Bondarev--CPN